ClinicalTrials.gg
Active, not recruitingNCT06634420Updated Oct 8, 2026

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

A Phase 3 interventional study of NTLA-2002 and Normal Saline IV Administration in Hereditary Angioedema, sponsored by Intellia Therapeutics. Active, not recruiting at 29 sites in 9 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Intellia Therapeutics · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 84 studies in Angioedemas, Hereditary with a site in United States — 12 open to participants now, 18 under way, 10 of them phase 3. Angioedemas, Hereditary · United States.

Enrollment
32nd of 74
80 · median 57
Started
2025
with 11 others
Phase 3
38 of 84
6 open now
Primary completion
2026-02
later than 0 of 17 live
Registered
67th of 84
by date

Among the 84 studies in Angioedemas, Hereditary with a site in United States, this one is the 32nd largest by enrollment of the 74 interventional ones that give a count, is one of 12 that started in 2025, is one of 38 in phase 3, reaches primary completion later than 0 of the 17 other live ones, and was the 67th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

12 of the 84 studies in Angioedemas, Hereditary with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Angioedemas, Hereditary with a site in United States, or all of them as a file.
02

Study summary

This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.

Read the detailed description

This is a multinational, multicenter, double-blind, placebo-controlled study in which approximately 60 participants will be randomized in a 2:1 ratio to receive a single IV infusion of NTLA-2002 or placebo. After the Primary Observation Period (Week 1 through Week 28), participants will have the option to receive a blinded, single IV infusion of the opposite treatment. Following the Primary Observation Period, participants will enter the Long-Term Observation Period (76 weeks), for a total of 104 weeks. Including the Screening and Run-In Period, prior to the first blinded dosing, the total study duration is approximately 28 months.

03

Conditions studied

  • Hereditary Angioedema

Keywords

  • Hereditary Angioedema
  • NTLA-2002
  • HAE
  • HAE-C1INH-Type1 or -Type 2
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥16 years
  2. Clinical history consistent with HAE-C1INH-Type 1 or -Type 2
  3. Ability to provide evidence of HAE attacks (confirmed by the Investigator) to meet the screening requirement
  4. Must agree to refrain from the use of long-term prophylactic therapies from the start of the screening period through the end of the Primary Observation Period. PI must be in agreement that it is medically acceptable for the participant to do so.
  5. Must have access to, and the ability to use, on-demand medication(s) to treat potential angioedema attacks
  6. Adequate chemistry and hematology measures at screening
  7. Must agree not to participate in another interventional study for the duration of this trial.
  8. Must be capable of providing signed . Participants 16 to \< 18 years of age, whose legal guardian provides informed consent, must provide assent.
  9. Must agree to follow requirements

Exclusion criteria

Exclusion Criteria:

  1. Concurrent diagnosis of any other type of recurrent angioedema or HAE with normal C1-INH
  2. Have known negative reaction or to any lipid nanoparticles (LNP) component.
  3. Any condition that, in the Investigator's opinion, could adversely affect the safety of the subject.
  4. Unwilling to comply with study procedures.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    Arm A: NTLA-2002

    Arm A: NTLA-2002 (50 mg; single IV infusion)

    Biological: NTLA-2002

  • Placebo comparator
    Arm B: Placebo

    Arm B: Placebo (saline; single IV infusion)

    Biological: Normal Saline IV Administration

Interventions

  • BiologicalNTLA-2002

    CRISPR/Cas9 gene editing system delivered by lipid nanoparticle (LNP) for intravenous (IV) administration

  • BiologicalNormal Saline IV Administration

    The administration of intravenous (IV) normal saline

06

What researchers measure

Primary outcomes

  1. Time-normalized number of Investigator-confirmed HAE attacks

    Time frame: From Week 5 through Week 28

Secondary outcomes

  1. Time-normalized number of Investigator-confirmed HAE attacks requiring on-demand treatment

    Time frame: From Week 5 through Week 28

  2. Time-normalized number of moderate or severe Investigator-confirmed HAE attacks

    Time frame: From Week 5 through Week 28

  3. Investigator-confirmed HAE attack-free status

    Time frame: From Week 5 through Week 28

  4. Change from baseline to Week 28 in AE-QoL Questionnaire total score

    Time frame: From baseline to Week 28

  5. Responder status, defined as reduction from baseline of at least 50%, 70%, and 90% in time-normalized number of Investigator-confirmed HAE attacks

    Time frame: From Week 5 through Week 28

  6. Time-normalized number of Investigator-confirmed HAE attacks

    Time frame: From Week 1 through Week 28

  7. Time-normalized number of Investigator-confirmed HAE attacks requiring on-demand treatment

    Time frame: from Week 1 through Week 28

  8. Time-normalized number of moderate or severe Investigator-confirmed HAE attacks

    Time frame: From Week 1 through Week 28

  9. Investigator-confirmed HAE attack-free status

    Time frame: From Week 1 through Week 28

  10. Reduction from baseline of at least 50%, 70%, and 90% in time-normalized number of Investigator-confirmed HAE attacks

    Time frame: From Week 1 through Week 28

  11. Long-term prophylaxis-free status

    Time frame: From Week 5 through Week 104

  12. HAE treatment-free status, defined as no usage of long-term prophylaxis or on-demand medication

    Time frame: From Week 5 through Week 104

  13. Complete responder status, defined as zero Investigator-confirmed attacks with no long-term prophylaxis

    Time frame: From Week 5 through Week 104

  14. Reduction in the time-normalized number of Investigator-confirmed HAE attacks after crossover treatment (Week 33 through Week 104) compared to before crossover treatment (Screening through Week 28) in participants randomized to placebo

    Time frame: From Week 33 through Week 104 and from Screening through Week 28

07

Study locations

29 sites
08

References and documents

Publications

  • Cohn DM, Gurugama P, Longhurst HJ, Aygoren-Pursun E, Craig TJ, Farkas H, Jacobs J, Lumry WR, Magerl M, Peter J, Riedl MA, Maag D, Golden A, Shah MY, Sutherland A, Miller CR, Abdelhady AM, Xu Y, Butler JS, Lebwohl D, Leonard J, Banerji A; HAELO Investigators. Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema. N Engl J Med. 2026 Jun 13. doi: 10.1056/NEJMoa2600931. Online ahead of print. PubMed 42294842 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Feb 2026, 12 months.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 12 months is below that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2024
First posted
Oct 9, 2024
StartActual
Jan 15, 2025
Primary completionActual
Feb 10, 2026
CompletionEst.
Sep 2027
Results delay requested
Oct 6, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: registry dates
1 update, last Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Minor edits only
    + 1 other change: registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06634420
Lead sponsor
Intellia Therapeutics
Responsible party
Sponsor
First posted
Oct 9, 2024
Start date
Jan 15, 2025
Primary completion
Feb 10, 2026
Completion
Sep 2027 (estimated)
Last update
Oct 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion